Introduction

Antoanella Calame, Clay J Cockerell

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

As the severity of the disease began to be understood and it became apparent that a worldwide pandemic was underway, our resourcefulness in the face of a new infectious agent was soon to be tested. In the early years following its description, AIDS was universally fatal and there seemed to be no cure in sight. Even after discovery of HIV, the causative agent of AIDS, treatment was primarily supportive and mortality rates continued to be high. While initially hopes for development of more effective therapy and an effective vaccine were high, infection as well as lack of political interest delayed much needed research funding. The first anti - retroviral medication, azidothymidine (AZT), was approved in 1987, 6 years after the first reports of AIDS. Over the next 10 years, better understanding of the disease, both scientifically and publicly, led to greater funding and accelerated research. Multiple new medications were approved by the Food and Drug Administration (FDA) in the US, and by 1997, regimens known as highly active antiretroviral therapy (HAART) gave new hope of transforming HIV infection from a death sentence to a chronic, manageable disease. With more effective long-term treatment and the ability to prevent or reduce transmission of HIV via early treatment after exposure and prenatal prophylaxis for affected mothers, a more optimistic view has arisen in the fight against HIV. Although development of an effective HIV vaccine remains elusive, worldwide focus on prevention, early diagnosis, and treatment have made significant impacts on the HIV pandemic, especially in developed countries. However, significant challenges remain, especially in devel - oping countries that are often fraught with problems of political unrest, general lack of education regarding HIV/AIDS, and social and cultural stigmata that hinder safe sex practices. Furthermore, side-effects of HAART, many of which are addressed in other chapters in this book, may cause individuals with HIV infection to discontinue taking med - ications, which can result in a recrudescence of immunodeficiency. Finally, and potentially most disheartening, recent data show that many men who exposed. Thus, it behoves physicians and caretakers to maintain a high degree of vigilance about the possibility of HIV/AIDS in their patients as the virus continues to maintain a high degree of prevalence in many countries, including the US.

Original languageEnglish (US)
Title of host publicationCutaneous Manifestations of HIV Disease
PublisherCRC Press
Pages9-10
Number of pages2
ISBN (Electronic)9781840766042
ISBN (Print)9781840761429
DOIs
StatePublished - Jan 1 2012

Fingerprint

HIV
Acquired Immunodeficiency Syndrome
Hope
Highly Active Antiretroviral Therapy
Pandemics
HIV Infections
Social Stigma
Safe Sex
Active Immunotherapy
AIDS Vaccines
Aptitude
Zidovudine
United States Food and Drug Administration
Therapeutics
Research
Developed Countries
Early Diagnosis
Chronic Disease
Mothers
Viruses

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Calame, A., & Cockerell, C. J. (2012). Introduction. In Cutaneous Manifestations of HIV Disease (pp. 9-10). CRC Press. https://doi.org/10.1201/b15910

Introduction. / Calame, Antoanella; Cockerell, Clay J.

Cutaneous Manifestations of HIV Disease. CRC Press, 2012. p. 9-10.

Research output: Chapter in Book/Report/Conference proceedingChapter

Calame, A & Cockerell, CJ 2012, Introduction. in Cutaneous Manifestations of HIV Disease. CRC Press, pp. 9-10. https://doi.org/10.1201/b15910
Calame A, Cockerell CJ. Introduction. In Cutaneous Manifestations of HIV Disease. CRC Press. 2012. p. 9-10 https://doi.org/10.1201/b15910
Calame, Antoanella ; Cockerell, Clay J. / Introduction. Cutaneous Manifestations of HIV Disease. CRC Press, 2012. pp. 9-10
@inbook{41aa6d8121874eaf9e01fb86b5e9b6f7,
title = "Introduction",
abstract = "As the severity of the disease began to be understood and it became apparent that a worldwide pandemic was underway, our resourcefulness in the face of a new infectious agent was soon to be tested. In the early years following its description, AIDS was universally fatal and there seemed to be no cure in sight. Even after discovery of HIV, the causative agent of AIDS, treatment was primarily supportive and mortality rates continued to be high. While initially hopes for development of more effective therapy and an effective vaccine were high, infection as well as lack of political interest delayed much needed research funding. The first anti - retroviral medication, azidothymidine (AZT), was approved in 1987, 6 years after the first reports of AIDS. Over the next 10 years, better understanding of the disease, both scientifically and publicly, led to greater funding and accelerated research. Multiple new medications were approved by the Food and Drug Administration (FDA) in the US, and by 1997, regimens known as highly active antiretroviral therapy (HAART) gave new hope of transforming HIV infection from a death sentence to a chronic, manageable disease. With more effective long-term treatment and the ability to prevent or reduce transmission of HIV via early treatment after exposure and prenatal prophylaxis for affected mothers, a more optimistic view has arisen in the fight against HIV. Although development of an effective HIV vaccine remains elusive, worldwide focus on prevention, early diagnosis, and treatment have made significant impacts on the HIV pandemic, especially in developed countries. However, significant challenges remain, especially in devel - oping countries that are often fraught with problems of political unrest, general lack of education regarding HIV/AIDS, and social and cultural stigmata that hinder safe sex practices. Furthermore, side-effects of HAART, many of which are addressed in other chapters in this book, may cause individuals with HIV infection to discontinue taking med - ications, which can result in a recrudescence of immunodeficiency. Finally, and potentially most disheartening, recent data show that many men who exposed. Thus, it behoves physicians and caretakers to maintain a high degree of vigilance about the possibility of HIV/AIDS in their patients as the virus continues to maintain a high degree of prevalence in many countries, including the US.",
author = "Antoanella Calame and Cockerell, {Clay J}",
year = "2012",
month = "1",
day = "1",
doi = "10.1201/b15910",
language = "English (US)",
isbn = "9781840761429",
pages = "9--10",
booktitle = "Cutaneous Manifestations of HIV Disease",
publisher = "CRC Press",

}

TY - CHAP

T1 - Introduction

AU - Calame, Antoanella

AU - Cockerell, Clay J

PY - 2012/1/1

Y1 - 2012/1/1

N2 - As the severity of the disease began to be understood and it became apparent that a worldwide pandemic was underway, our resourcefulness in the face of a new infectious agent was soon to be tested. In the early years following its description, AIDS was universally fatal and there seemed to be no cure in sight. Even after discovery of HIV, the causative agent of AIDS, treatment was primarily supportive and mortality rates continued to be high. While initially hopes for development of more effective therapy and an effective vaccine were high, infection as well as lack of political interest delayed much needed research funding. The first anti - retroviral medication, azidothymidine (AZT), was approved in 1987, 6 years after the first reports of AIDS. Over the next 10 years, better understanding of the disease, both scientifically and publicly, led to greater funding and accelerated research. Multiple new medications were approved by the Food and Drug Administration (FDA) in the US, and by 1997, regimens known as highly active antiretroviral therapy (HAART) gave new hope of transforming HIV infection from a death sentence to a chronic, manageable disease. With more effective long-term treatment and the ability to prevent or reduce transmission of HIV via early treatment after exposure and prenatal prophylaxis for affected mothers, a more optimistic view has arisen in the fight against HIV. Although development of an effective HIV vaccine remains elusive, worldwide focus on prevention, early diagnosis, and treatment have made significant impacts on the HIV pandemic, especially in developed countries. However, significant challenges remain, especially in devel - oping countries that are often fraught with problems of political unrest, general lack of education regarding HIV/AIDS, and social and cultural stigmata that hinder safe sex practices. Furthermore, side-effects of HAART, many of which are addressed in other chapters in this book, may cause individuals with HIV infection to discontinue taking med - ications, which can result in a recrudescence of immunodeficiency. Finally, and potentially most disheartening, recent data show that many men who exposed. Thus, it behoves physicians and caretakers to maintain a high degree of vigilance about the possibility of HIV/AIDS in their patients as the virus continues to maintain a high degree of prevalence in many countries, including the US.

AB - As the severity of the disease began to be understood and it became apparent that a worldwide pandemic was underway, our resourcefulness in the face of a new infectious agent was soon to be tested. In the early years following its description, AIDS was universally fatal and there seemed to be no cure in sight. Even after discovery of HIV, the causative agent of AIDS, treatment was primarily supportive and mortality rates continued to be high. While initially hopes for development of more effective therapy and an effective vaccine were high, infection as well as lack of political interest delayed much needed research funding. The first anti - retroviral medication, azidothymidine (AZT), was approved in 1987, 6 years after the first reports of AIDS. Over the next 10 years, better understanding of the disease, both scientifically and publicly, led to greater funding and accelerated research. Multiple new medications were approved by the Food and Drug Administration (FDA) in the US, and by 1997, regimens known as highly active antiretroviral therapy (HAART) gave new hope of transforming HIV infection from a death sentence to a chronic, manageable disease. With more effective long-term treatment and the ability to prevent or reduce transmission of HIV via early treatment after exposure and prenatal prophylaxis for affected mothers, a more optimistic view has arisen in the fight against HIV. Although development of an effective HIV vaccine remains elusive, worldwide focus on prevention, early diagnosis, and treatment have made significant impacts on the HIV pandemic, especially in developed countries. However, significant challenges remain, especially in devel - oping countries that are often fraught with problems of political unrest, general lack of education regarding HIV/AIDS, and social and cultural stigmata that hinder safe sex practices. Furthermore, side-effects of HAART, many of which are addressed in other chapters in this book, may cause individuals with HIV infection to discontinue taking med - ications, which can result in a recrudescence of immunodeficiency. Finally, and potentially most disheartening, recent data show that many men who exposed. Thus, it behoves physicians and caretakers to maintain a high degree of vigilance about the possibility of HIV/AIDS in their patients as the virus continues to maintain a high degree of prevalence in many countries, including the US.

UR - http://www.scopus.com/inward/record.url?scp=85055491780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055491780&partnerID=8YFLogxK

U2 - 10.1201/b15910

DO - 10.1201/b15910

M3 - Chapter

AN - SCOPUS:85055491780

SN - 9781840761429

SP - 9

EP - 10

BT - Cutaneous Manifestations of HIV Disease

PB - CRC Press

ER -